Database Locked for the Rare Disease Pediatric Study

GCT team is proud of taking part in the achievement of the major milestone for the Phase III clinical trial. The study is being successfully conducted, amidst the present difficult global environment, in pediatric patients suffering from a rare neurological disease. It is a randomized, double-blind, placebo-controlled trial followed by a long-term open label treatment. In January 2020, GCT successfully completed the enrollment of patients in Russia. We have now reached the next milestone – the Database Lock.

Despite all the challenges caused by the pandemic, the GCT team was able to follow each patient closely and ensure they complete all the required assessments, keeping trial participants safe during the treatment stage. This trial required a high level of GCT expertise and involvement, which the team successfully delivered.

“The sponsor of this trial, a US Pharmaceutical company, demonstrated an incredible level of trust in GCT, for which we are extremely grateful. We hope that our professional relationship will continue to grow and develop in the future,” – Dr. Eugene Selivra, GCT CEO.

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

About

GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login

 

GCT

© 2001—2020 Global Clinical Trials, LLC

All rights reserved.